Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes

Drug Metabolism and Disposition

Volumn 27, Issue 11, 1999, Pages 1334-1340

  Wienkers, Larry C ^a,b   Allievi, Cecilia ^a   Hauer, Michael J ^a   Wynalda, Michael A ^a  

^a PFIZER INC   (United States)

^b Drug Metab and Disposition Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450; KETOCONAZOLE; REBOXETINE;

AEROBIC METABOLISM; ARTICLE; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; ENANTIOMER; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MICHAELIS MENTEN KINETICS; MICROSOME; OXIDATION; PRIORITY JOURNAL;

ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; MICROSOMES, LIVER; MORPHOLINES; RECOMBINANT PROTEINS; STEREOISOMERISM;

INSECTA; UNIDENTIFIED BACULOVIRUS;

EID: 0032750751     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bertz RJ and Granneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258.
2. Caldwell J (1995) Stereochemical determinants of the nature and consequences of drug metabolism. J Chromatogr A 694:39-48.
3. Cheng Y and Prusoff WH (1973) Relationship between the inhihition constant (ki) and the concentration of inhibitor which causes 50 per cent inhibition IC50 of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
4. Cocchiara G, Battaglia R, Pevarello P and Strolin-Benedetti M (1991) Comparison of the disposition and of the metabolic pattern of Reboxetine, a new antidepressant, in the rat, dog, monkey and man. Eur J Drug Metab Pharmacokinet 16:231-239.
5. Desta Z, Kerbusch T, Soukhova N, Richard E, Ko JW and Flockhart DA (1998) Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther 285:428-437.
6. Dostert P, Benedetti MS and Poggesi I (1997) Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol 7 (Suppl 1):S23-35.
7. Draper AJ, Madan A and Parkinson A (1997) Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch Biochem Biophys 341:47-61.
8. Dubini A, Bosc M and Polin V (1997) Noradrenaline-selective versus serotonin-selective antidepressant therapy: Differential effects on social functioning. J Psychopharmacol (Oxf) 11 (Suppl 4):S17-23.
9. Edwards DM, Pellizzoni C, Breuel HP, Berardi A, Castelli MG, Frigerio E, Poggesi I, Rocchetti M, Dubini A and Strolin-Benedetti M (1995) Pharmacokinetics of reboxetine in healthy volunteers: Single oral doses, linearity and plasma protein binding. Biopharm Drug Dispos 16:443-450.
10. Fleishaker JC, Pearson LK and Peters GR (1995) Phenytoin causes a rapid increase in 6 beta-hydroxycortisol urinary excretion in humans, a putative measure of CYP3A induction. J Pharm Sci 84:292-294.
11. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP and Hebert MF (1997) Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 62(1):41-49.
12. Gelboin HV, Krausz KW, Goldfarb I, Buters JTM, Yang SK, Gonzalez FJ, Korzekwa KR and Shou M (1995) Inhibitory and noninhibitory monoclonal antibodies to human P450 3A3/4. Biochem Pharmacol 50:1841-1850.
13. Guengerich FP, Muller-Enoch D and Blair IA (1986) Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 30:287-295.
14. Halliday RC, Jones BC, Smith DA, Kitteringham NR and Park BK (1995) An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: Studies with human liver microsomes and heterologous enzyme expression systems. Br J Clin Pharmacol 40:369-378.
15. Hindmarch I (1997) The effects of antidepressants on psychomotor function with particular reference to reboxetine. Eur Neuropsychopharmacol 7 (Suppl 1):S17-21.
16. m values: Implications for clinical correlation. J Pharmacol Exp Ther 282:391-396.
17. Melloni P, Della Torre A, Lazzari E, Mazzini G and Meroni M (1985) Configuration studies on 2-[α-(2-ethoxyphenoxy)benzyl]-morpholine FCE 20124. Tetrahedron 41:1393-1399.
18. Montgomery SA (1997) Is there a role for a pure noradrenergic drug in the treatment of depression? Eur Neuropsychopharmacol 7 (Suppl 1):S3-9.
19. Mucci M (1997)Reboxetine: A review of antidepressant tolerability. J Psychopharmacol (Oxf) 11 (4 Suppl):S33-37.
20. Newton DJ, Wang RW and Lu AY (1995) Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
21. Obach RS (1997) Nonspecific binding to microsomes: Impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol. Drug Metab Dispos 25:1359-1369.
22. Pearce RE, Rodrigues AD, Goldstein JA and Parkinson A (1996) Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 277:805-816.
23. Pichard L, Fahre I, Fabre G, Domergue J, Saint-Aubert B, Mourad G and Maurel P (1990) Cyclosporin A drug interactions: Screening for inducers and inhibitors of cytochrome P-450 (cyclosnorin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 18:595-606.
24. Rane A, Wilkinson GR and Shand DG (1977) Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J Pharmacol Exp Ther 200:420-424.
25. Rocchetti M, Pellizzoni C, Poggesi I, Wilkins MR, Hirokawa K, Dostert P and Strolin-Benedelti M (1995) Genetic polymorphism and reboxetine metabolism: 1st Congress of the Eureopean Association for Clinical Pharmacology and Therapeutics (Abstract 80). Therapie (Suppl).
26. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
27. Strolin-Benedetti M, Pellizzoni C, Poggesi I, Dostert P and Dubini A (1994) Pharmacokinetics of reboxetine enantiomers in healthy volunteers. Can J Physiol Pharmacol 72 (Suppl 1):441.
28. Wienkers LC, Steenwyk RC, Sanders PE and Pearson PG (1996) Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes. J Pharmacol Exp Ther 277:982-990.
29. Wilkinson GR (1996) Cytochrome P4503A (CYP3A) metabolism: Prediction of in vivo activity in humans. J Pharmacokinet Biopharm 24:475-490.
30. Wrighton SA, VandenBranden M and Ring BJ (1996) The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm 24:461-473.
31. Wynalda MA and Wienkers LC (1997) Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos 25:1211-1214.
32. Xu D, Voigt JM, Mice BA, Kominami S, Takemori S and Colby HD (1994) Inhibition of adrenal cytochromes P450 by 1-aminobenzotriazole in vitro: Selectivity for xenobiotic metabolism. Biochem Pharmacol 48:1421-1426.